TP53 and non-small cell lung carcinoma: Reports have shown that the occurrence of TP53 mutations in primary tumors and metastatic lymph nodes in NSCLC was 23.2% and 21.4%, respectively, with reported frequencies varying by geographical region [12,13,14,15,16].